RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

Benzinga Newsdesk www.benzinga.com Positive 91.1%

Neg 0% Neu 0% Pos 91.1%

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.